Expert Insights

Do you consider other risk factors beyond advanced age and history of thrombosis?

Read transcript Close transcript

I consider classic cardiovascular risk factors as something that would worry me and want me to make sure that a patient has a better controlled hematocrit. Someone who has diabetes or had a high-grade heart attack, those are patients I would worry about in addition to age and prior thrombosis of wanting to control their hematocrit tightly. I'm worried about what resistance to prior therapy means in terms of hematocrit control, not by itself being necessarily a biomarker that they have worse disease. And then excessive symptoms or complications with PV—that's a concerning feature that would want me to make sure that a patient has a better controlled hematocrit.

head shot of Dr Dao
Kim-Hien Dao, DO, PhD Assistant Professor of Medicine Knight Cancer Institute, Center for Hematologic Malignancies Oregon Health & Science University | Portland, OR
Dr Kim-Hien Dao serves as the Myelodysplastic Syndromes (MDS)–Myeloproliferative Neoplasms (MPN) Disease Group Leader at the Center for Hematologic Malignancies at Oregon Health & Science University. She is a member of the American Society of Hematology and Myeloproliferative Disorders (MPD) Research Consortium and is active in clinical research trials in MDS and MPNs. Dr Dao has an NIH-funded basic research program focusing on marrow failure in Fanconi anemia, myelodysplasia, and MPNs.